Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249264 | 0.90 | POLB (0.52) | SMN1; SMN2MAPTNPC1MAOBRAB9A | |
| SCHEMBL29592689 | 0.90 | POLB (0.52) | SMN1; SMN2MAPTNPC1MAOBRAB9A | |
| SCHEMBL4256577 | 0.84 | AKR1B1 (0.67) | SMN1; SMN2MAPTNPC1MAOBRAB9A | |
| SCHEMBL7163440 | 0.84 | MIF (0.67) | MAPTMAOBGAAMIFPFKFB3 | |
| SCHEMBL4253620 | 0.81 | MAOB (0.66) | SMN1; SMN2MAPTMAOBAKR1B1 | |
| SCHEMBL2246104 | 0.80 | MAPT (0.51) | SMN1; SMN2MAPTNPC1MAOBRAB9A | |
| SCHEMBL10717733 | 0.80 | CA12 (0.52) | SMN1; SMN2MAPTNPC1MAOBRAB9A | |
| SCHEMBL742193 | 0.79 | MIF (0.68) | SMN1; SMN2MAPTMAOBRAB9AGAA | |
| SCHEMBL28367859 | 0.79 | CYP1A2 (0.50) | MAPTNPC1MAOBRAB9AGAA | |
| SCHEMBL1091343 | 0.79 | MAOA (0.51) | SMN1; SMN2MAPTNPC1MAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-08 | — | — | US | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005082866-A2 | SUBSTITUTED 1, 2, 4- TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174488-A1 | SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, SARS1, ACE | SMN1; SMN2 4477/4885MAPT 1411/4885NPC1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.